logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Matthias Pinter

Medical University of Vienna
H指数:55
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Blood- and Liver Stiffness-Based Non-Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC

基于血液和肝脏硬度检测的无创性检查在慢性肝纤维化相关肝硬化及肝癌患者中临床显著门静脉高压的诊断应用

Liver International
IF5.2
2026-10-280
OAAI
Lorenz Balcar; Tina Jasmin Haunold; Mathias Jachs; Georg Semmler; Benedikt Simbrunner; Albert Friedrich Stättermayer; David Pereyra; Christoph Schwarz; Stefan Stremitzer; Klaus Kaczirek; Patrick Starlinger; Peter Quehenberger; Michael Trauner; Bernhard Scheiner; Thomas Reiberger; Matthias Pinter; Mattias Mandorfer
ALBI ‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab

ALBI‐6——一种结合ALBI和白细胞介素‐6的新型预后评分，用于接受阿替利珠单抗和贝伐珠单抗治疗的HCC患者

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
IF6.7
2026-10-080
OAAI
Paula Bark; Lucas Wiesmann; Simon Johannes Gairing; Kateryna Shmanko; Lukas Müller; Maximilian Moos; Fabian Stöhr; Dirk Graafen; Tilman Emrich; Felix Hahn; Daniel Pinto dos Santos; Bernhard Scheiner; Victoria Berit Berger; Matthias Pinter; Valentina Zarka; Florian P. Reiter; Andreas Geier; Najib Ben Khaled; Alexander Philipp; Christoph Springfeld; Aurelie Tomczak; Michael T. Dill; Constantin Scholz; Jens Mittler; Hauke Lang; Beate Katharina Straub; Roman Kloeckner; Tobias Bäuerle; Christian Markus Lange; Arndt Weinmann; Peter Robert Galle; Friedrich Foerster
FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study

FMT联合阿替利珠单抗-贝伐珠单抗在免疫治疗耐药的肝细胞癌中的应用：一项开放标签、单臂、II期初步研究

Nature Communications
IF15.7
2026-10-070
OA
Katharina Pomej; Adrian Frick; Bernhard Scheiner; Maximilian Baumgartner; Klaus G. Schmetterer; Carlos S. Reyna-Blanco; Lorenz Balcar; Larissa Pajancic; Abelina Kreuter; Joana Séneca; Bela Hausmann; Thomas Köcher; Melanie Prinzensteiner; Katharina Lampichler; Nataliya Rohr-Udilova; Adrija Chakrabarty; Anton Klotz; Annika C. Lampl; Kerstin Zinober; Katharina Regnat; Michael Trauner; David Berry; Dietmar Tamandl; Thomas Vogl; Christoph Gasche; Matthias Pinter
CAPTYN, a Blood-Based Machine Learning Model Predicting Clinical Benefit of Atezolizumab–Bevacizumab in Hepatocellular Carcinoma: Validation in IMbrave150 Trial

CAPTYN，一种基于血液的机器学习模型预测阿替利珠单抗–贝伐珠单抗在肝细胞癌中的临床获益：IMbrave150试验中的验证

Cancer Communications
IF24.9
2026-09-290
OA
Gae Hoon Jo; Sohyun Hwang; Bernhard Scheiner; Seonjeong Woo; Won Suk Lee; Beodeul Kang; Jung Sun Kim; Ho Yeong Lim; Chansik An; Dong Yun Kim; Inyoung Kim; Dong-hyuk Heo; Matthias Pinter; Beom Kyung Kim; Chan Kim; Hong Jae Chon
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.

髓系免疫抑制表型定义了肝细胞癌对阿替利珠单抗联合贝伐珠单抗的原发耐药性。

Journal of Hepatology
IF33
2026-06-150
OAAI
Pasquale Lombardi; Erik Ramon-Gil; Rabial Q. Raja; Leonardo Brunetti; Giulia Francesca Manfredi; Zhongguo Zhou; George Merces; Sarah Cappuyns; Claudia Angela Maria Fulgenzi; Antonio D’Alessio; Aria Torkpour; Ciro Celsa; Bernardo Stefanini; Hannah Yang; Fionnuala Crowley; Thomas U. Marron; Anwaar Saeed; Matthias Pinter; Bernhard Scheiner; Yi-Hsiang Huang
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE Score

预测阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌患者的失代偿：ARTE评分

Clinical Gastroenterology and Hepatology
IF12
2026-05-260
PRE
Lorenzo Canova; Eleonora Alimenti; Lorenzo Argiento; Giuseppe Cabibbo; Francesco Tovoli; Emanuela Di Giacomo; Peter R. Galle; Ciro Celsa; Matthias Pinter; Thomas U. Marron; Caterina Vivaldi; Andrea Dalbeni; Fabio Marra; Andrea Palloni; Sara Lonardi; Francesca Romana Ponziani; Piera Federico; Anwaar Saeed; Anjana Pillai; Tiziana Pressiani
Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma—Data From the Multinational LITCHI Registry

免疫检查点抑制剂治疗后肝细胞癌患者的肝移植——来自跨国LITCHI登记研究的数据

Liver International
IF5.2
2026-05-190
OAAI
Ulrike Bauer; Maria R. Troppmair; Najib Ben Khaled; Julia M. Grottenthaler; Friedrich Foerster; Sena Blümel; Sophia Heinrich; Friedrich Sinner; Matthias Pinter; Magdalena Hahn; Florian van Bömmel; Bernhard Scheiner; Marino Venerito; Richard Taubert; Andreas E. Kremer; Arndt Weinmann; Christoph P. Berg; Christian M. Lange; Enrico N. De Toni; Angela Djanani; Heinz Zoller; Roland M. Schmid; Ursula Ehmer
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

不可切除肝细胞癌患者接受阿替利珠单抗联合贝伐珠单抗长期生存的影响因素

European Journal of Cancer
IF7.1
2026-04-160
PRE
Pei-Chang Lee; Alessio Cortellini; Bernardo Stefanini; Changhoon Yoo; Hong Jae Chon; Jaekyung Cheon; Masatoshi Kudo; Naoshi Nishida; Bernhard Scheiner; Matthias Pinter; Pasquale Lombardi; Claudia Angela Maria Fulgenzi; Antonio D'Alessio; Leonardo Brunetti; Aria Torkpour; Elena Valenzi; Fionnuala Crowley; Thomas U Marron; Wei-Fan Hsu; Ciro Celsa
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)

CheckMate 9DW研究的通俗总结：纳武利尤单抗联合伊匹木单抗治疗不可切除的肝细胞癌（晚期肝癌）

Future Oncology
IF2.6
2026-04-140
PRE
Thomas Yau; Peter R Galle; Thomas Decaens; Bruno Sangro; Shukui Qin; Leonardo G da Fonseca; Hatim Karachiwala; Jean-Frederic Blanc; Joong-Won Park; Edward Gane; Matthias Pinter; Ana Matilla Peña; Masafumi Ikeda; David Tai; Armando Santoro; Gonzalo Pizarro; Chang-Fang Chiu; Michael Schenker; Aiwu He; Hong Jae Chon; Joanna Wojcik-Tomaszewska; Gontran Verset; Qi Qi Wang; Caitlyn Stromko; Jaclyn Neely; Prianka Singh; Maria Jesus Jimenez Exposito; Masatoshi Kudo
Non-invasive tests to guide hepatocellular carcinoma surveillance☆

指导肝细胞癌监测 ☆ 的非侵入性测试

JHEP Reports
IF7.5
2026-01-230
OAAI
Jan EMBACHER; Katharina REMIH; Carolin Victoria SCHNEIDER; Mathias JACHS; Lorenz BALCAR; Paul THÖNE; Christian SEBESTA; Nina DOMINIK; Georg KRAMER; Benedikt Silvester HOFER; Lukas HARTL; Benedikt SIMBRUNNER; Bernhard SCHEINER; Matthias PINTER; Michael TRAUNER; Thomas REIBERGER; Pavel STRNAD; Georg SEMMLER; Mattias MANDORFER
The Alpha-1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLD
Alimentary Pharmacology & Therapeutics
IF6.7
2026-01-230
OAAI
Lorenz Balcar; Georg Semmler; Bernhard Scheiner; Rafael Paternostro; Benedikt Simbrunner; Tina Jasmin Haunold; Mathias Jachs; Lukas Hartl; Benedikt Silvester Hofer; Nina Dominik; Michael Schwarz; Georg Kramer; Christian Sebesta; Paul Thöne; Matthias Pinter; Michael Trauner; Thomas Reiberger; Albert Friedrich Stättermayer; Mattias Mandorfer
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: results of the DT-real study

在临床实践中，durvalumab联合或单药使用tremelimumab治疗肝细胞癌的可重复安全性及有效性：DT-real研究结果

JHEP Reports
IF7.5
2025-11-200
OAAI
Ciro Celsa; Tiziana Pressiani; Naoshi Nishida; Shadi Mohamad Chamseddine; Ashwini Arvind; Michael Li; Marta Fortuny; Najib Ben Khaled; Massimo Iavarone; Hidenori Toyoda; Ilario Giovanni Rapposelli; Andrea Casadei-Gardini; Caterina Vivaldi; Susanna Ulahannan; Haripriya Andanamala; Bernhard Scheiner; Matthias Pinter; Elena Orlandi; Claudia A.M. Fulgenzi; Giulia F. Manfredi
Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease-Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute-on-Chronic Liver Failure and Death

靛青绿清除率与反映晚期慢性肝病关键疾病驱动机制的生物标志物相关，并可预测急性-慢性肝功能衰竭及死亡。

Alimentary Pharmacology & Therapeutics
IF6.7
2025-11-050
OAAI
Mathias Jachs; Tânia Carvalho; Benedikt Simbrunner; Georg Semmler; Lukas Hartl; Lorenz Balcar; Benedikt Silvester Hofer; Paul Thöne; Nina Dominik; Georg Kramer; Christian Sebesta; Michael Schwarz; David Bauer; Albert F. Stättermayer; Matthias Pinter; Michael Trauner; Thomas Reiberger; Mattias Mandorfer
Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study

伦伐替尼对比索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌的二线治疗：LEVIATHAN 研究

JHEP Reports
IF7.5
2025-09-230
OAAI
Pasquale Lombardi; Jung Sun Kim; Giulia F. Manfredi; Ciro Celsa; Claudia A.M. Fulgenzi; Antonio D’Alessio; Bernardo Stefanini; Niraj C. Doshi; Emily Warmington; Thomas U. Marron; Matthias Pinter; Bernhard Scheiner; Beodeul Kang; Ho Yeong Lim; Wei-Fan Hsu; Brooke Wietharn; Marianna Silletta; Alessandro Parisi; Chun-Yen Lin; Andrea Dalbeni; Gianluca Masi; Martin Schönlein; Johann von Felden; Fabio Piscaglia; Peter R. Galle; Masatoshi Kudo; Tiziana Pressiani; Lorenza Rimassa; Mario Pirisi; Giuseppe Cabibbo; Hong Jae Chon; David J. Pinato

研究方向

暂未获取到该数据
B
Bernhard Scheiner
H 指数:43论文数:384被引数:7,523
M
Michael Trauner
H 指数:128论文数:3,382被引数:6.7万
T
Thomas Reiberger
H 指数:72论文数:1,098被引数:2.1万
M
Mattias Mandorfer
H 指数:57论文数:794被引数:1.4万
L
Lorenz Balcar
H 指数:27论文数:330被引数:2,811
B
Benedikt Simbrunner
H 指数:32论文数:290被引数:3,320
M
Markus Peck‐Radosavljevic
H 指数:84论文数:767被引数:2.6万
G
Georg Semmler
H 指数:36论文数:392被引数:4,039
W
Wolfgang Sieghart
H 指数:39论文数:238被引数:6,520
D
David J. Pinato
H 指数:66论文数:866被引数:1.7万